Article(id=1329830625349054974, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329830490300854592, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2023.08.015, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1669564800000, receivedDateStr=2022-11-28, revisedDate=1676131200000, revisedDateStr=2023-02-12, acceptedDate=null, acceptedDateStr=null, onlineDate=1794985928141, onlineDateStr=2026-11-18, pubDate=1691596800000, pubDateStr=2023-08-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794985928141, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794985928141, creator=13701087609, updateTime=1794985928141, updator=13701087609, issue=Issue{id=1329830490300854592, tenantId=1146029695717560320, journalId=1319690329412173987, year='2023', volume='44', issue='8', pageStart='767', pageEnd='890', issueExtLink='null', onlineDate='null', pubDate='1691596800000', pubDateStr='2023-08-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794985895943, creator='13701087609', updateTime=1794987961153, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329839152994038236, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329830490300854592, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329839152994038237, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329830490300854592, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=858, endPage=864, ext={EN=ArticleExt(id=1329830627051942399, articleId=1329830625349054974, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Research on bortezomib-based regimens for the treatment of multiple myeloma, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Multiple myeloma (MM) is a hematologic tumor resulting from the malignant proliferation of monoclonal plasma cells in the bone marrow. In recent years, the extensive application of proteasome inhibitor (PI), immunomodulators and autologous or allogeneic stem cell transplantation have significantly improved the remission rate, survival rate and prognosis of MM patients. Bortezomib (BTZ) is a PI, which is effective in the treatment of MM in clinical practice. This article reviewed the progress of BTZ-based treatment of MM, aiming to provide some reference for clinical use.

, authors=Jingxue LIU, Jia YI, Deduo XU, Shengyan YANG, Xia TAO*, authorsList=Jingxue LIU, Jia YI, Deduo XU, Shengyan YANG, Xia TAO, authorCompany=null, correspAuthors=Xia TAO, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329830627270046208, articleId=1329830625349054974, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=以硼替佐米为基础治疗多发性骨髓瘤研究进展, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

多发性骨髓瘤(multiple myeloma,MM)是一种骨髓内单克隆浆细胞恶性增殖导致的血液肿瘤。近年来,蛋白酶体抑制剂(proteasome inhibitor,PI)、免疫调节剂及自体或异体干细胞移植等方案的广泛应用,显著提高MM患者缓解率及生存率,并改善预后。硼替佐米(bortezomib,BTZ)是一种PI,临床治疗MM成效明显。现结合既往文献对以BTZ为基础治疗MM的进展作一综述,旨在为临床提供一定参考。

, authors=刘景雪, 伊佳, 徐德铎, 杨胜岩, 陶霞*, authorsList=刘景雪, 伊佳, 徐德铎, 杨胜岩, 陶霞, authorCompany=null, correspAuthors=陶霞, authorNote=

刘景雪,初级药师,研究方向:中药活性成分作用机制研究。

, correspAuthorsNote=
陶霞,主任药师,研究方向:临床药学与心血管药理学。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=8Je5CgCJwDzohE9xTYD6ig==, magXml=GZ+oOJpZTLHNIxHFEOlRHw==, pdfUrl=null, pdf=URkLu1yq+ksOqOxUsLbnaA==, pdfFileSize=1595546, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=g1HnipogGhp0Ldi8/Nm7Aw==, mapNumber=null, fund=null)}, authors=[Author(id=1329830627496538629, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329830627572036103, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, authorId=1329830627496538629, language=EN, stringName=Jingxue LIU, firstName=Jingxue, middleName=null, lastName=LIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmacy, the Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329830627634950664, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, authorId=1329830627496538629, language=CN, stringName=刘景雪, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=海军军医大学第二附属医院药剂科,上海 200003, bio={"content":"

刘景雪,初级药师,研究方向:中药活性成分作用机制研究。

"}, bioImg=null, bioContent=

刘景雪,初级药师,研究方向:中药活性成分作用机制研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329830627425235457, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, xref=null, ext=[AuthorCompanyExt(id=1329830627433624066, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, companyId=1329830627425235457, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, the Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China), AuthorCompanyExt(id=1329830627442012675, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, companyId=1329830627425235457, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=海军军医大学第二附属医院药剂科,上海 200003)])]), Author(id=1329830627706253834, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329830627802722828, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, authorId=1329830627706253834, language=EN, stringName=Jia YI, firstName=Jia, middleName=null, lastName=YI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmacy, the Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329830627853054477, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, authorId=1329830627706253834, language=CN, stringName=伊佳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=海军军医大学第二附属医院药剂科,上海 200003, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329830627425235457, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, xref=null, ext=[AuthorCompanyExt(id=1329830627433624066, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, companyId=1329830627425235457, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, the Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China), AuthorCompanyExt(id=1329830627442012675, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, companyId=1329830627425235457, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=海军军医大学第二附属医院药剂科,上海 200003)])]), Author(id=1329830627932746255, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329830628016632337, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, authorId=1329830627932746255, language=EN, stringName=Deduo XU, firstName=Deduo, middleName=null, lastName=XU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmacy, the Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329830628087935506, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, authorId=1329830627932746255, language=CN, stringName=徐德铎, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=海军军医大学第二附属医院药剂科,上海 200003, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329830627425235457, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, xref=null, ext=[AuthorCompanyExt(id=1329830627433624066, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, companyId=1329830627425235457, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, the Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China), AuthorCompanyExt(id=1329830627442012675, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, companyId=1329830627425235457, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=海军军医大学第二附属医院药剂科,上海 200003)])]), Author(id=1329830628146655764, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329830628230541846, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, authorId=1329830628146655764, language=EN, stringName=Shengyan YANG, firstName=Shengyan, middleName=null, lastName=YANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmacy, the Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329830628297650711, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, authorId=1329830628146655764, language=CN, stringName=杨胜岩, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=海军军医大学第二附属医院药剂科,上海 200003, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329830627425235457, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, xref=null, ext=[AuthorCompanyExt(id=1329830627433624066, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, companyId=1329830627425235457, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, the Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China), AuthorCompanyExt(id=1329830627442012675, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, companyId=1329830627425235457, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=海军军医大学第二附属医院药剂科,上海 200003)])]), Author(id=1329830628352176665, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329830628423479835, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, authorId=1329830628352176665, language=EN, stringName=Xia TAO, firstName=Xia, middleName=null, lastName=TAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Pharmacy, the Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329830628482200092, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, authorId=1329830628352176665, language=CN, stringName=陶霞, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=海军军医大学第二附属医院药剂科,上海 200003, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329830627425235457, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, xref=null, ext=[AuthorCompanyExt(id=1329830627433624066, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, companyId=1329830627425235457, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, the Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China), AuthorCompanyExt(id=1329830627442012675, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, companyId=1329830627425235457, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=海军军医大学第二附属医院药剂科,上海 200003)])])], keywords=[Keyword(id=1329830628566086173, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, language=EN, orderNo=1, keyword=bortezomib), Keyword(id=1329830628624806430, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, language=EN, orderNo=2, keyword=multiple myeloma), Keyword(id=1329830628683526687, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, language=EN, orderNo=3, keyword=proteasome inhibitor), Keyword(id=1329830628750635552, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, language=EN, orderNo=4, keyword=adverse reaction), Keyword(id=1329830628826133025, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, language=CN, orderNo=1, keyword=硼替佐米), Keyword(id=1329830628889047586, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, language=CN, orderNo=2, keyword=多发性骨髓瘤), Keyword(id=1329830628943573539, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, language=CN, orderNo=3, keyword=蛋白酶体抑制剂), Keyword(id=1329830629002293796, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, language=CN, orderNo=4, keyword=不良反应)], refs=[Reference(id=1329830629203620390, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Avet-Loiseau H. Introduction to a review series on advances in multiple myeloma[J]. Blood, 2019, 133(7): 621., articleTitle=null, refAbstract=null), Reference(id=1329830629262340647, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Usmani SZ, Hoering A, Cavo M, et al. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma an IMWG research project[J]. Blood Cancer J, 2018, 8(12): 123., articleTitle=null, refAbstract=null), Reference(id=1329830629321060904, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Schmidt TM, Barwick BG, Joseph N, et al. Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone[J]. Blood Cancer J, 2019, 9(12): 94., articleTitle=null, refAbstract=null), Reference(id=1329830629379781161, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Usmani SZ, Hoering A, Ailawadhi S, et al. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial[J]. Lancet Haematol, 2021, 8(1): e45-e54., articleTitle=null, refAbstract=null), Reference(id=1329830629455278634, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Bai Y, Su X. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma[J]. Asia Pac J Clin Oncol, 2021, 17(1): 29-35., articleTitle=null, refAbstract=null), Reference(id=1329830629530776108, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Levin A, Hari P, Dhakal B. Novel biomarkers in multiple myeloma[J]. Transl Res, 2018, 201: 49-59., articleTitle=null, refAbstract=null), Reference(id=1329830629602079277, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Veggiani G, Gerpe MCR, Sidhu SS, et al. Emerging drug development technologies targeting ubiquitination for cancer therapeutics[J]. Pharmacol Ther, 2019, 199: 139-154., articleTitle=null, refAbstract=null), Reference(id=1329830629664993838, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Lu Z, Hunter T. Ubiquitylation and proteasomal degradation of the p21 (Cip1), p27 (Kip1) and p57 (Kip2) CDK inhibitors[J]. Cell Cycle, 2010, 9(12): 2342-2352., articleTitle=null, refAbstract=null), Reference(id=1329830629727908399, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation[J]. Science, 2011, 334(6059): 1081-1086., articleTitle=null, refAbstract=null), Reference(id=1329830629786628656, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Vrábel D, Pour L, Ševčíková S. The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma[J]. Blood Rev, 2019, 34: 56-66., articleTitle=null, refAbstract=null), Reference(id=1329830631397241393, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Liu Y, Wang X, Zhu T, et al. Resistance to bortezomib in breast cancer cells that downregulate Bim through FOXA1 O-GlcNAcylation[J]. J Cell Physiol, 2019, 234(10): 17527-17537., articleTitle=null, refAbstract=null), Reference(id=1329830631497904690, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Huynh M, Pak C, Markovina S, et al. Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma[J]. J Biol Chem, 2018, 293(7): 2452-2465., articleTitle=null, refAbstract=null), Reference(id=1329830631556624947, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Matthews GM, Matos Simoes R, Dhimolea E, et al. NF-κB dysregulation in multiple myeloma[J]. Semin Cancer Biol, 2016, 39: 68-76., articleTitle=null, refAbstract=null), Reference(id=1329830631648899636, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Rasche L, Chavan SS, Stephens OW, et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing[J]. Nat Commun, 2017, 8(1): 268., articleTitle=null, refAbstract=null), Reference(id=1329830631728591413, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Yerlikaya A, Okur E, Tarik Baykal A, et al. Data for a proteomic analysis of p53-independent induction of apoptosis by bortezomib[J]. Data Brief, 2014, 1: 56-69., articleTitle=null, refAbstract=null), Reference(id=1329830631791505974, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Yerlikaya A, Okur E, Baykal AT, et al. A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line[J]. J Proteomics, 2015, 113: 315-325., articleTitle=null, refAbstract=null), Reference(id=1329830631883780663, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Oerlemans R, Franke NE, Assaraf YG, et al. Molecular basis of bortezomib resistance: proteasome subunit β5(PSMB5) gene mutation and overexpression of PSMB5 protein[J]. Blood, 2008, 112(6): 2489-2499., articleTitle=null, refAbstract=null), Reference(id=1329830631950889528, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Murray MY, Auger MJ, Bowles KM. Overcoming bortezomib resistance in multiple myeloma[J]. Biochem Soc Trans, 2014, 42(4): 804-808., articleTitle=null, refAbstract=null), Reference(id=1329830632043164217, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Lohr JG, Kim S, Gould J, et al. Genetic interrogation of circulating multiple myeloma cells at single-cell resolution[J]. Sci Transl Med, 2016, 8(363): 363ra147., articleTitle=null, refAbstract=null), Reference(id=1329830632101884474, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Gasparini C, Celeghini C, Monasta L, et al. NF-κB pathways in hematological malignancies[J]. Cell Mol Life Sci, 2014, 71(11): 2083-2102., articleTitle=null, refAbstract=null), Reference(id=1329830632177381947, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Lewis T, Corcoran DB, Thurston DE, et al. Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-κB activity and synergise with bortezomib and ibrutinib in hematological cancers[J]. Haematologica, 2021, 106(4): 958-967., articleTitle=null, refAbstract=null), Reference(id=1329830632236102204, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Yi H, Liang L, Wang H, et al. Albendazole inhibits NF-κB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma[J]. Cancer Lett, 2021, 520: 307-320., articleTitle=null, refAbstract=null), Reference(id=1329830632311599677, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Labbadia J, Morimoto RI. The biology of proteostasis in aging and disease[J]. Annu Rev Biochem, 2015, 84: 435-464., articleTitle=null, refAbstract=null), Reference(id=1329830632387097150, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Chen X, Cubillos-Ruiz JR. Endoplasmic reticulum stress signals in the tumour and its microenvironment[J]. Nat Rev Cancer, 2021, 21(2): 71-88., articleTitle=null, refAbstract=null), Reference(id=1329830632454206015, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Sun CY, Li JY, Chu ZB, et al. Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis[J]. Biosci Rep, 2017, 37(4): BSR20170304., articleTitle=null, refAbstract=null), Reference(id=1329830632517120576, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial[J]. Lancet, 2017, 389(10068): 519-527., articleTitle=null, refAbstract=null), Reference(id=1329830632580035137, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase Ⅲ trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)[J]. Blood Cancer J, 2020, 10(5): 53., articleTitle=null, refAbstract=null), Reference(id=1329830632651338306, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma[J]. N Engl J Med, 2017, 376(14): 1311-1320., articleTitle=null, refAbstract=null), Reference(id=1329830632714252867, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Perrot A, Lauwers-Cances V, Cazaubiel T, et al. Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial[J]. Blood, 2020, 136(Suppl 1): 39., articleTitle=null, refAbstract=null), Reference(id=1329830632827499076, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study[J]. Lancet, 2010, 376(9758): 2075-2085., articleTitle=null, refAbstract=null), Reference(id=1329830632890413637, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Rosiñol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study[J]. Blood, 2012, 120(8): 1589-1596., articleTitle=null, refAbstract=null), Reference(id=1329830632974299718, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Giri S, Grimshaw A, Bal S, et al. Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis[J]. J Am Med Assoc Oncol, 2020, 6(11): 1759-1765., articleTitle=null, refAbstract=null), Reference(id=1329830633037214279, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Goldman-Mazur S, Kumar SK. Current approaches to management of high-risk multiple myeloma[J]. Am J Hematol, 2021, 96(7): 854-871., articleTitle=null, refAbstract=null), Reference(id=1329830633116906056, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of to taltherapy 3[J]. Br J Haematol, 2007, 138(2): 176-185., articleTitle=null, refAbstract=null), Reference(id=1329830633175626313, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial[J]. Blood, 2020, 136(8): 936-945., articleTitle=null, refAbstract=null), Reference(id=1329830633255318090, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Kaiser MF, Hall A, Walker K, et al. Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma[J]. J Clin Oncol, 2023, 14: 1-12., articleTitle=null, refAbstract=null), Reference(id=1329830633314038347, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Kouroukis CT, Baldassarre FG, Haynes AE, et al. Bortezomib in multiple myeloma: a practice guideline[J]. Clin Oncol (R Coll Radiol), 2014, 26(2): 110-119., articleTitle=null, refAbstract=null), Reference(id=1329830633376952908, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Xie JD, Chen SR, Chen H, et al. Bortezomib induces neuropathic pain through protein kinase C-mediated activation of presynaptic NMDA receptors in the spinal cord[J]. Neuropharmacology, 2017, 123: 477-487., articleTitle=null, refAbstract=null), Reference(id=1329830633435673165, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=Li T, Timmins HC, King T, et al. Characteristics and risk factors of bortezomib induced peripheral neuropathy: a systematic review of phase Ⅲ trials[J]. Hematol Oncol, 2020, 38(3): 229-243., articleTitle=null, refAbstract=null), Reference(id=1329830633506976334, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=Yao R, Hu X, Zhou S, et al. Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China[J]. Medicine (Baltimore), 2019, 98(39): e17147., articleTitle=null, refAbstract=null), Reference(id=1329830633578279503, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=Gonsalves WI, Buadi FK, Ailawadhi S, et al. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement[J]. Bone Marrow Transplant, 2019, 54(3): 353-367., articleTitle=null, refAbstract=null), Reference(id=1329830633649582672, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=Velasco R, Alberti P, Bruna J, et al. Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: from pathogenesis to treatment[J]. J Peripher Nerv Syst, 2019, 24(Suppl 2): S52-S62., articleTitle=null, refAbstract=null), Reference(id=1329830633729274449, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=Han XY, Jin CX, Zheng GF, et al. Different patient subgroup different maintenance, proteasome inhibitors or immunomodulators maintenance for newly diagnosed multiple myeloma: a 7-year single-center data in China[J]. Front Oncol, 2021, 11: 665217., articleTitle=null, refAbstract=null), Reference(id=1329830633808966226, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhang HM, Liu XY, Liu YZ, et al. Analysis of the efficacy and safety of bortezomib for treating newly diagnosed multiple myeloma through different administration methods[J]. Cancer Manag Res, 2019, 11: 8295-8302., articleTitle=null, refAbstract=null), Reference(id=1329830633880269395, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=Dai TY, Chen CC, Hong LL, et al. Effect evaluation of strychnos nux-vomica L. with integrative methods for bortezomib-induced peripheral neuropathy in multiple myeloma patients: a self-controlled clinical trial[J]. Chin J Integr Med, 2021, 27(2): 131-136., articleTitle=null, refAbstract=null), Reference(id=1329830633943183956, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=Thawani SP, Tanji K, De Sousa EA, et al. Bortezomib-associated demyelinating neuropathy-clinical and pathologic features[J]. J Clin Neuromuscul Dis, 2015, 16(4): 202-209., articleTitle=null, refAbstract=null), Reference(id=1329830634048041557, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=Yan W, Wu Z, Zhang Y, et al. The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy[J]. Biomed Pharmacother, 2021, 24: 112068., articleTitle=null, refAbstract=null), Reference(id=1329830634119344726, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=Stockstill K, Doyle TM, Yan X, et al. Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain[J]. J Exp Med, 2018, 215(5): 1301-1313., articleTitle=null, refAbstract=null), Reference(id=1329830634190647895, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[49], rfOrder=48, authorNames=null, journalName=null, refType=null, unstructuredReference=Cengiz Seval G, Beksac M, et al. The safety of bortezomib for the treatment of multiple myeloma[J]. Expert Opin Drug Saf, 2018, 17(9): 953-962., articleTitle=null, refAbstract=null), Reference(id=1329830634249368152, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[50], rfOrder=49, authorNames=null, journalName=null, refType=null, unstructuredReference=Ludwig H, Delforge M, Facon T, et al. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European myeloma network[J]. Leukemia, 2018, 32(7): 1542-1560., articleTitle=null, refAbstract=null), Reference(id=1329830635872563801, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[51], rfOrder=50, authorNames=null, journalName=null, refType=null, unstructuredReference=Cole DC, Frishman WH. Cardiovascular complications of proteasome inhibitors used in multiple myeloma[J]. Cardiol Rev, 2018, 26(3): 122-129., articleTitle=null, refAbstract=null), Reference(id=1329830635994198618, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[52], rfOrder=51, authorNames=null, journalName=null, refType=null, unstructuredReference=Burkhart T, Keith MCL, Lenneman CAG, et al. Bortezomib-induced cardiac tamponade in a 49-year-old man[J]. Tex Heart Inst J, 2018, 45(4): 260-263., articleTitle=null, refAbstract=null), Reference(id=1329830636086473307, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[53], rfOrder=52, authorNames=null, journalName=null, refType=null, unstructuredReference=Meseeha MG, Kolade VO, Attia MN. Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy[J]. J Community Hosp Intern Med Perspect, 2015, 5(6): 28982., articleTitle=null, refAbstract=null), Reference(id=1329830636182942300, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[54], rfOrder=53, authorNames=null, journalName=null, refType=null, unstructuredReference=Cornell RF, Ky B, Weiss BM, et al. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma[J]. Clin Oncol, 2019, 37(22): 1946-1955., articleTitle=null, refAbstract=null), Reference(id=1329830636271022685, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[55], rfOrder=54, authorNames=null, journalName=null, refType=null, unstructuredReference=Yui JC, Van Keer J, Weiss BM, et al. Proteasome inhibitor associated thrombotic microangiopathy: proteasome inhibitor associated TMA[J]. Am J Hematol, 2016, 91(9): E348-E352., articleTitle=null, refAbstract=null), Reference(id=1329830636329742942, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[56], rfOrder=55, authorNames=null, journalName=null, refType=null, unstructuredReference=Tamura D, Arao T, Tanaka K, et al. Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition[J]. Cancer Sci, 2010, 101(6): 1403-1408., articleTitle=null, refAbstract=null), Reference(id=1329830636388463199, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[57], rfOrder=56, authorNames=null, journalName=null, refType=null, unstructuredReference=Herrmann J, Wohlert C, Saguner AM, et al. Primary proteasome inhibition results in cardiac dysfunction[J]. Eur J Heart Fail, 2013, 15(6): 614-623., articleTitle=null, refAbstract=null), Reference(id=1329830636463960672, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[58], rfOrder=57, authorNames=null, journalName=null, refType=null, unstructuredReference=Guglielmi V, Nowis D, Tinelli M, et al. Bortezomib-induced muscle toxicity in multiple myeloma[J]. Neuropathol Exp Neurol, 2017, 76(7): 620-630., articleTitle=null, refAbstract=null), Reference(id=1329830636556235361, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[59], rfOrder=58, authorNames=null, journalName=null, refType=null, unstructuredReference=Pancheri E, Guglielmi V, Wilczynski GM, et al. Non-hematologic toxicity of bortezomib in multiple myeloma: the neuromuscular and cardiovascular adverse effects[J]. Cancers (Basel), 2020, 12(9): 2540., articleTitle=null, refAbstract=null), Reference(id=1329830636627538530, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[60], rfOrder=59, authorNames=null, journalName=null, refType=null, unstructuredReference=Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study[J]. Lancet, 2019, 394(10192): 29-38., articleTitle=null, refAbstract=null)], funds=[Fund(id=1329830629102957093, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, awardId=SHYXH-ZP-2021-005, language=CN, fundingSource=上海药学会药物临床综合评价与药物治疗路径(SHYXH-ZP-2021-005), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1329830627425235457, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, xref=null, ext=[AuthorCompanyExt(id=1329830627433624066, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, companyId=1329830627425235457, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, the Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China), AuthorCompanyExt(id=1329830627442012675, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, companyId=1329830627425235457, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=海军军医大学第二附属医院药剂科,上海 200003)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.08.015, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.08.015, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2023.08.015, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2023.08.015, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1691596800000, fullTextJson=null, articleText=null, reference=null)
收藏切换
以硼替佐米为基础治疗多发性骨髓瘤研究进展
刘景雪 , 伊佳 , 徐德铎 , 杨胜岩 , 陶霞 *
世界临床药物 | 综述评论 2023,44(8): 858-864
收起
收藏切换
世界临床药物 |综述评论 2023 , 44 (8) : 858 -864
以硼替佐米为基础治疗多发性骨髓瘤研究进展
全屏
[Author(id=1329830627496538629, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329830627572036103, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, authorId=1329830627496538629, language=EN, stringName=Jingxue LIU, firstName=Jingxue, middleName=null, lastName=LIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmacy, the Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329830627634950664, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, authorId=1329830627496538629, language=CN, stringName=刘景雪, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=海军军医大学第二附属医院药剂科,上海 200003, bio={"content":"

刘景雪,初级药师,研究方向:中药活性成分作用机制研究。

"}, bioImg=null, bioContent=

刘景雪,初级药师,研究方向:中药活性成分作用机制研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329830627425235457, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, xref=null, ext=[AuthorCompanyExt(id=1329830627433624066, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, companyId=1329830627425235457, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, the Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China), AuthorCompanyExt(id=1329830627442012675, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, companyId=1329830627425235457, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=海军军医大学第二附属医院药剂科,上海 200003)])]), Author(id=1329830627706253834, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329830627802722828, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, authorId=1329830627706253834, language=EN, stringName=Jia YI, firstName=Jia, middleName=null, lastName=YI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmacy, the Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329830627853054477, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, authorId=1329830627706253834, language=CN, stringName=伊佳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=海军军医大学第二附属医院药剂科,上海 200003, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329830627425235457, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, xref=null, ext=[AuthorCompanyExt(id=1329830627433624066, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, companyId=1329830627425235457, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, the Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China), AuthorCompanyExt(id=1329830627442012675, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, companyId=1329830627425235457, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=海军军医大学第二附属医院药剂科,上海 200003)])]), Author(id=1329830627932746255, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329830628016632337, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, authorId=1329830627932746255, language=EN, stringName=Deduo XU, firstName=Deduo, middleName=null, lastName=XU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmacy, the Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329830628087935506, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, authorId=1329830627932746255, language=CN, stringName=徐德铎, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=海军军医大学第二附属医院药剂科,上海 200003, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329830627425235457, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, xref=null, ext=[AuthorCompanyExt(id=1329830627433624066, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, companyId=1329830627425235457, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, the Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China), AuthorCompanyExt(id=1329830627442012675, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, companyId=1329830627425235457, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=海军军医大学第二附属医院药剂科,上海 200003)])]), Author(id=1329830628146655764, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329830628230541846, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, authorId=1329830628146655764, language=EN, stringName=Shengyan YANG, firstName=Shengyan, middleName=null, lastName=YANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmacy, the Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329830628297650711, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, authorId=1329830628146655764, language=CN, stringName=杨胜岩, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=海军军医大学第二附属医院药剂科,上海 200003, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329830627425235457, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, xref=null, ext=[AuthorCompanyExt(id=1329830627433624066, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, companyId=1329830627425235457, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, the Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China), AuthorCompanyExt(id=1329830627442012675, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, companyId=1329830627425235457, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=海军军医大学第二附属医院药剂科,上海 200003)])]), Author(id=1329830628352176665, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329830628423479835, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, authorId=1329830628352176665, language=EN, stringName=Xia TAO, firstName=Xia, middleName=null, lastName=TAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Pharmacy, the Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329830628482200092, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, authorId=1329830628352176665, language=CN, stringName=陶霞, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=海军军医大学第二附属医院药剂科,上海 200003, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329830627425235457, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, xref=null, ext=[AuthorCompanyExt(id=1329830627433624066, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, companyId=1329830627425235457, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, the Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China), AuthorCompanyExt(id=1329830627442012675, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830625349054974, companyId=1329830627425235457, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=海军军医大学第二附属医院药剂科,上海 200003)])])]
刘景雪, 伊佳, 徐德铎, 杨胜岩, 陶霞*
作者信息
  • 海军军医大学第二附属医院药剂科,上海 200003
通讯作者:
陶霞,主任药师,研究方向:临床药学与心血管药理学。
作者简介:

刘景雪,初级药师,研究方向:中药活性成分作用机制研究。

Research on bortezomib-based regimens for the treatment of multiple myeloma
Jingxue LIU, Jia YI, Deduo XU, Shengyan YANG, Xia TAO*
Affiliations
  • Department of Pharmacy, the Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China
出版时间: 2023-08-10 doi: 10.13683/j.wph.2023.08.015
文章导航
收藏切换

多发性骨髓瘤(multiple myeloma,MM)是一种骨髓内单克隆浆细胞恶性增殖导致的血液肿瘤。近年来,蛋白酶体抑制剂(proteasome inhibitor,PI)、免疫调节剂及自体或异体干细胞移植等方案的广泛应用,显著提高MM患者缓解率及生存率,并改善预后。硼替佐米(bortezomib,BTZ)是一种PI,临床治疗MM成效明显。现结合既往文献对以BTZ为基础治疗MM的进展作一综述,旨在为临床提供一定参考。

硼替佐米  /  多发性骨髓瘤  /  蛋白酶体抑制剂  /  不良反应

Multiple myeloma (MM) is a hematologic tumor resulting from the malignant proliferation of monoclonal plasma cells in the bone marrow. In recent years, the extensive application of proteasome inhibitor (PI), immunomodulators and autologous or allogeneic stem cell transplantation have significantly improved the remission rate, survival rate and prognosis of MM patients. Bortezomib (BTZ) is a PI, which is effective in the treatment of MM in clinical practice. This article reviewed the progress of BTZ-based treatment of MM, aiming to provide some reference for clinical use.

bortezomib  /  multiple myeloma  /  proteasome inhibitor  /  adverse reaction
刘景雪, 伊佳, 徐德铎, 杨胜岩, 陶霞. 以硼替佐米为基础治疗多发性骨髓瘤研究进展. 世界临床药物, 2023 , 44 (8) : 858 -864 . DOI: 10.13683/j.wph.2023.08.015
Jingxue LIU, Jia YI, Deduo XU, Shengyan YANG, Xia TAO. Research on bortezomib-based regimens for the treatment of multiple myeloma[J]. World Clinical Drug, 2023 , 44 (8) : 858 -864 . DOI: 10.13683/j.wph.2023.08.015
  • 上海药学会药物临床综合评价与药物治疗路径(SHYXH-ZP-2021-005)
参考文献 引证文献
排序方式:
[1]
Avet-Loiseau H. Introduction to a review series on advances in multiple myeloma[J]. Blood, 2019, 133(7): 621.
[2]
Usmani SZ, Hoering A, Cavo M, et al. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma an IMWG research project[J]. Blood Cancer J, 2018, 8(12): 123.
[3]
Schmidt TM, Barwick BG, Joseph N, et al. Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone[J]. Blood Cancer J, 2019, 9(12): 94.
[4]
Usmani SZ, Hoering A, Ailawadhi S, et al. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial[J]. Lancet Haematol, 2021, 8(1): e45-e54.
[5]
Bai Y, Su X. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma[J]. Asia Pac J Clin Oncol, 2021, 17(1): 29-35.
[6]
Levin A, Hari P, Dhakal B. Novel biomarkers in multiple myeloma[J]. Transl Res, 2018, 201: 49-59.
[7]
Veggiani G, Gerpe MCR, Sidhu SS, et al. Emerging drug development technologies targeting ubiquitination for cancer therapeutics[J]. Pharmacol Ther, 2019, 199: 139-154.
[8]
Lu Z, Hunter T. Ubiquitylation and proteasomal degradation of the p21 (Cip1), p27 (Kip1) and p57 (Kip2) CDK inhibitors[J]. Cell Cycle, 2010, 9(12): 2342-2352.
[9]
Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation[J]. Science, 2011, 334(6059): 1081-1086.
[10]
Vrábel D, Pour L, Ševčíková S. The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma[J]. Blood Rev, 2019, 34: 56-66.
[11]
Liu Y, Wang X, Zhu T, et al. Resistance to bortezomib in breast cancer cells that downregulate Bim through FOXA1 O-GlcNAcylation[J]. J Cell Physiol, 2019, 234(10): 17527-17537.
[12]
Huynh M, Pak C, Markovina S, et al. Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma[J]. J Biol Chem, 2018, 293(7): 2452-2465.
[13]
Matthews GM, Matos Simoes R, Dhimolea E, et al. NF-κB dysregulation in multiple myeloma[J]. Semin Cancer Biol, 2016, 39: 68-76.
[14]
Rasche L, Chavan SS, Stephens OW, et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing[J]. Nat Commun, 2017, 8(1): 268.
[15]
Yerlikaya A, Okur E, Tarik Baykal A, et al. Data for a proteomic analysis of p53-independent induction of apoptosis by bortezomib[J]. Data Brief, 2014, 1: 56-69.
[16]
Yerlikaya A, Okur E, Baykal AT, et al. A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line[J]. J Proteomics, 2015, 113: 315-325.
[17]
Oerlemans R, Franke NE, Assaraf YG, et al. Molecular basis of bortezomib resistance: proteasome subunit β5(PSMB5) gene mutation and overexpression of PSMB5 protein[J]. Blood, 2008, 112(6): 2489-2499.
[18]
Murray MY, Auger MJ, Bowles KM. Overcoming bortezomib resistance in multiple myeloma[J]. Biochem Soc Trans, 2014, 42(4): 804-808.
[19]
Lohr JG, Kim S, Gould J, et al. Genetic interrogation of circulating multiple myeloma cells at single-cell resolution[J]. Sci Transl Med, 2016, 8(363): 363ra147.
[20]
Gasparini C, Celeghini C, Monasta L, et al. NF-κB pathways in hematological malignancies[J]. Cell Mol Life Sci, 2014, 71(11): 2083-2102.
[21]
Lewis T, Corcoran DB, Thurston DE, et al. Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-κB activity and synergise with bortezomib and ibrutinib in hematological cancers[J]. Haematologica, 2021, 106(4): 958-967.
[22]
Yi H, Liang L, Wang H, et al. Albendazole inhibits NF-κB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma[J]. Cancer Lett, 2021, 520: 307-320.
[23]
Labbadia J, Morimoto RI. The biology of proteostasis in aging and disease[J]. Annu Rev Biochem, 2015, 84: 435-464.
[24]
Chen X, Cubillos-Ruiz JR. Endoplasmic reticulum stress signals in the tumour and its microenvironment[J]. Nat Rev Cancer, 2021, 21(2): 71-88.
[25]
Sun CY, Li JY, Chu ZB, et al. Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis[J]. Biosci Rep, 2017, 37(4): BSR20170304.
[26]
Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial[J]. Lancet, 2017, 389(10068): 519-527.
[27]
Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase Ⅲ trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)[J]. Blood Cancer J, 2020, 10(5): 53.
[28]
Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma[J]. N Engl J Med, 2017, 376(14): 1311-1320.
[29]
Perrot A, Lauwers-Cances V, Cazaubiel T, et al. Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial[J]. Blood, 2020, 136(Suppl 1): 39.
[30]
Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study[J]. Lancet, 2010, 376(9758): 2075-2085.
[31]
Rosiñol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study[J]. Blood, 2012, 120(8): 1589-1596.
[32]
Giri S, Grimshaw A, Bal S, et al. Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis[J]. J Am Med Assoc Oncol, 2020, 6(11): 1759-1765.
[33]
Goldman-Mazur S, Kumar SK. Current approaches to management of high-risk multiple myeloma[J]. Am J Hematol, 2021, 96(7): 854-871.
[34]
Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of to taltherapy 3[J]. Br J Haematol, 2007, 138(2): 176-185.
[35]
Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial[J]. Blood, 2020, 136(8): 936-945.
[36]
Kaiser MF, Hall A, Walker K, et al. Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma[J]. J Clin Oncol, 2023, 14: 1-12.
[37]
Kouroukis CT, Baldassarre FG, Haynes AE, et al. Bortezomib in multiple myeloma: a practice guideline[J]. Clin Oncol (R Coll Radiol), 2014, 26(2): 110-119.
[38]
Xie JD, Chen SR, Chen H, et al. Bortezomib induces neuropathic pain through protein kinase C-mediated activation of presynaptic NMDA receptors in the spinal cord[J]. Neuropharmacology, 2017, 123: 477-487.
[39]
Li T, Timmins HC, King T, et al. Characteristics and risk factors of bortezomib induced peripheral neuropathy: a systematic review of phase Ⅲ trials[J]. Hematol Oncol, 2020, 38(3): 229-243.
[40]
Yao R, Hu X, Zhou S, et al. Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China[J]. Medicine (Baltimore), 2019, 98(39): e17147.
[41]
Gonsalves WI, Buadi FK, Ailawadhi S, et al. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement[J]. Bone Marrow Transplant, 2019, 54(3): 353-367.
[42]
Velasco R, Alberti P, Bruna J, et al. Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: from pathogenesis to treatment[J]. J Peripher Nerv Syst, 2019, 24(Suppl 2): S52-S62.
[43]
Han XY, Jin CX, Zheng GF, et al. Different patient subgroup different maintenance, proteasome inhibitors or immunomodulators maintenance for newly diagnosed multiple myeloma: a 7-year single-center data in China[J]. Front Oncol, 2021, 11: 665217.
[44]
Zhang HM, Liu XY, Liu YZ, et al. Analysis of the efficacy and safety of bortezomib for treating newly diagnosed multiple myeloma through different administration methods[J]. Cancer Manag Res, 2019, 11: 8295-8302.
[45]
Dai TY, Chen CC, Hong LL, et al. Effect evaluation of strychnos nux-vomica L. with integrative methods for bortezomib-induced peripheral neuropathy in multiple myeloma patients: a self-controlled clinical trial[J]. Chin J Integr Med, 2021, 27(2): 131-136.
[46]
Thawani SP, Tanji K, De Sousa EA, et al. Bortezomib-associated demyelinating neuropathy-clinical and pathologic features[J]. J Clin Neuromuscul Dis, 2015, 16(4): 202-209.
[47]
Yan W, Wu Z, Zhang Y, et al. The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy[J]. Biomed Pharmacother, 2021, 24: 112068.
[48]
Stockstill K, Doyle TM, Yan X, et al. Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain[J]. J Exp Med, 2018, 215(5): 1301-1313.
[49]
Cengiz Seval G, Beksac M, et al. The safety of bortezomib for the treatment of multiple myeloma[J]. Expert Opin Drug Saf, 2018, 17(9): 953-962.
[50]
Ludwig H, Delforge M, Facon T, et al. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European myeloma network[J]. Leukemia, 2018, 32(7): 1542-1560.
[51]
Cole DC, Frishman WH. Cardiovascular complications of proteasome inhibitors used in multiple myeloma[J]. Cardiol Rev, 2018, 26(3): 122-129.
[52]
Burkhart T, Keith MCL, Lenneman CAG, et al. Bortezomib-induced cardiac tamponade in a 49-year-old man[J]. Tex Heart Inst J, 2018, 45(4): 260-263.
[53]
Meseeha MG, Kolade VO, Attia MN. Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy[J]. J Community Hosp Intern Med Perspect, 2015, 5(6): 28982.
[54]
Cornell RF, Ky B, Weiss BM, et al. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma[J]. Clin Oncol, 2019, 37(22): 1946-1955.
[55]
Yui JC, Van Keer J, Weiss BM, et al. Proteasome inhibitor associated thrombotic microangiopathy: proteasome inhibitor associated TMA[J]. Am J Hematol, 2016, 91(9): E348-E352.
[56]
Tamura D, Arao T, Tanaka K, et al. Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition[J]. Cancer Sci, 2010, 101(6): 1403-1408.
[57]
Herrmann J, Wohlert C, Saguner AM, et al. Primary proteasome inhibition results in cardiac dysfunction[J]. Eur J Heart Fail, 2013, 15(6): 614-623.
[58]
Guglielmi V, Nowis D, Tinelli M, et al. Bortezomib-induced muscle toxicity in multiple myeloma[J]. Neuropathol Exp Neurol, 2017, 76(7): 620-630.
[59]
Pancheri E, Guglielmi V, Wilczynski GM, et al. Non-hematologic toxicity of bortezomib in multiple myeloma: the neuromuscular and cardiovascular adverse effects[J]. Cancers (Basel), 2020, 12(9): 2540.
[60]
Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study[J]. Lancet, 2019, 394(10192): 29-38.
2023年第44卷第8期
8
1
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2023.08.015
  • 接收时间:2022-11-28
  • 首发时间:2026-11-18
  • 出版时间:2023-08-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2022-11-28
  • 修回日期:2023-02-12
基金
上海药学会药物临床综合评价与药物治疗路径(SHYXH-ZP-2021-005)
作者信息
    海军军医大学第二附属医院药剂科,上海 200003

通讯作者:

陶霞,主任药师,研究方向:临床药学与心血管药理学。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.08.015
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏